Secondary analysis of 32 single-centre patients with ANCA-associated vasculitis in a placebo-controlled COVID-19 prophylaxis trial: ENT symptoms during treatment occurred in 1/14 (7%) on intranasal niclosamide vs 7/18 (39%) on placebo (P=0.04).
Secondary analysisn = 32
Lim et al. The Effect of Intranasal Niclosamide on Nasal Symptoms in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis